Anthropic’s IPO Filing Walks Back Bold Biology Claims as Company Prepares to Go Public

Anthropic filed for its IPO on October 27, 2026, and in doing so struck a notably more cautious tone about its ambitions in biology and drug discovery than the company and its CEO have previously expressed in public statements.

CEO Dario Amodei has made sweeping claims about AI’s potential in life sciences. Two years ago, he wrote that he was “open” to the idea that AI could produce a thousand years of progress in biology in just five to ten years. As recently as August 2026, he posted on X that AI will make it possible to cure most human diseases within five to ten years and promised a “deluge of AI-accelerated drugs.” The company also promoted what it described as a “Crispr-like” enzyme discovered by its Claude model in September 2026.

The IPO filing tells a more measured story. While it still claims AI can “profoundly accelerate the rate of progress in biology and medicine,” it acknowledges that Anthropic’s teams “need first-hand experience doing scientific research and drug discovery” and that its life sciences work will require activities “outside our historical experience as a software and research organization” — including handling hazardous materials, operating lab equipment, and navigating regulatory requirements.

The filing also softened language around the Claude enzyme discovery, describing it as something that “might have the potential to be developed into a novel biotechnology tool, perhaps for gene editing.” Researchers previously told WIRED they were skeptical of the discovery’s value, and one scientist studying the same enzymes raised concerns that Claude may have drawn on his unpublished work. Anthropic denied that either its model or its molecular biology team had access to that material.

The filing makes clear that Anthropic now views biotech discovery as a core part of its business, not just a use case for external clients. But it also concedes that “any drug candidates or other discoveries resulting from these efforts would face the lengthy, costly, and uncertain development and regulatory pathways characteristic of the life sciences industry, and may never generate revenue.”

That reality — that AI-assisted discoveries still require testing in labs, animals, and eventually human trials — means Anthropic faces the same slow timelines that constrain every biotech company, regardless of how much computing power is applied.